Neutrophil-Lymphocyte Ratio as a Prognostic Marker for Lung Adenocarcinoma after Complete Resection

World Journal of Surgery

Volumn 40, Issue 2, 2016, Pages 365-372

  Takahashi, Yusuke ^a,b   Kawamura, Masafumi ^b   Hato, Tai ^a   Harada, Masahiko ^a   Matsutani, Noriyuki ^b   Horio, Hirotoshi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NEOPLASMS; LYMPH VESSEL; LYMPHOCYTE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PLEURA; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC VESSELS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUTROPHILS; PLEURA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SMOKING; SURVIVAL RATE; YOUNG ADULT;

EID: 84955191549     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-015-3275-2     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS, Wu YL (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS ONE 7:e40109
3. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry (2008) A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 3:46-52
4. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA (2011) Non-small-cell lung cancer. Lancet non-small-cell lung cancer. Lancet 378:1727-1740
5. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil and lymphocyte ratio predicts survival in patients with various cancer. Br J Cancer 107:695-699
6. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, Cappuzzo F (2015) PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112:95-102
7. Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, So T, Sugio K, Yasumoto K (2005) Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy. Lung Cancer 48:281-289
8. Sun PL, Jin Y, Kim H, Seo AN, Jheon S, Lee CT, Chung JH (2013) Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma. Virchows Arch 463:427-436
9. Black CC, Turk MJ, Dragnev K, Rigas JR (2013) Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer. Lung 191:265-270
10. Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Kawasaki N, Konaka C, Kato H (2002) Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 37:161-169
11. Travis WDBE, Mueller-Hermelink HK, Harris CC (eds) (2002) World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
12. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706-714
13. Graziosi L, Marino E, De Angelis V, Rebonato A, Cavazzoni E, Donini A (2015) Prognostic value of preoperative neutrophils to lymphocytes ratio in patients resected for gastric cancer. Am J Surg 209:333-337
14. Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, Du C, Wang S, Wei B, Fu P (2014) Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Oncol Targets Ther 7:1743-1752
15. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000) Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60:184-190
16. Ben Q, An W, Wang L, Wang W, Yu L, Yuan Y (2015) Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma. Pancreas 44:471-477
17. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R (2013) Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108:901-907
18. Szkandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stotz M, Samonigg H, Glehr M, Zacherl M, Stojakovic T, Gerger A, Leithner A (2013) Elevated preoperative neutrophil/lymphocyte ratio is associated with prognosis in soft-tissue sarcoma patients. Br J Cancer 108:1677-1683
19. Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA (2014) Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer 110:1930-1935
20. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137:425-428
21. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T (2011) Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 31:2995-2998
22. Takahashi Y, Horio H, Hato T, Harada M, Matsutani N, Morita S, Kawamura M (2015) Prognostic significance of preoperative neutrophil-lymphocyte ratios in patients with stage I non-small cell lung cancer after complete resection. Ann Surg Oncol. doi: 10.1245/s10434-015-4735-5, Jul 22 2015)
23. Kundu JK, Surh YJ (2008) Inflammation: gearing the journey to cancer. Mutat Res 659:15-30
24. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. FASEB J 11:457-465
25. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436-444
26. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH (2001) Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer 1:7
27. Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, Amiral J, Richter V, Wagner OF (1999) Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 159:857-863
28. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small cell lung cancer: an analysis of japan Multinational Atrial Organization LC00-03. Eur J Cancer 45:1950-1958
29. Roxburg CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149-163
30. Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS, Youn TJ, Cho GY, Chae IH, Choi DJ (2013) Prognostic value of neutrophil to lymphocyte ratio in patients presenting ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 11:55-59
31. Sen N, Afsar B, Ozcan F, Buyukkaya E, Isleyen A, Akcay AB, Yuzgecer H, Kurt M, Karakas MF, Basar N, Hajro E, Kanbay M (2013) The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 228:203-210
32. Kocyigit I, Eroglu E, Unal A, Sipahioglu MH, Tokgoz B, Oymak O, Utas C (2013) Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. J Nephrol 26:358-365
33. Spark JI, Sarveswaran J, Blest N, Charalabidis P, Asthana S (2010) An elevated neutrophil-lymphocyte ratio independently predicts mortality in chronic critical limb ischemia. J Vasc Surg 52:632-636
34. Gökhan S, Ozhasenekler A, Mansur Durgun H, Akil E, Ustündag M, Orak M (2013) Neutrophil lymphocyte ratios in stroke subtypes and transient ischemic attack. Eur Rev Med Pharmacol Sci 17:653-657
35. Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T (2012) Elevated preoperative inflammatory markers based on neutrophil-to lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res 32:3535-3538
36. Uramoto H, So T, Nagata Y, Kuroda K, Shigematsu Y, Baba T, So T, Takenoyama M, Hanagiri T, Yasumoto K (2010) Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. J Thorac Oncol 5:1136-1142
37. Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, Li H, Luo X, Ye T, Sun Y, Chen H (2014) Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Oncol Targets Ther 7:567-573
38. Kinoshita T, Ishii G, Hiraoka N, Hirayama S, Yamauchi C, Aokage K et al (2013) Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma. Cancer Sci 104:409-415
39. Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis WD, Sadelain M, Adusumilli PS (2013) Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 31:490-498
40. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2013) Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 11:645-653
41. Kwon MJ, Seo J, Kim YJ, Kwon MJ, Choi JY, Kim TE, Lee DH, Park S, Shin YK, Han J, Choi YL (2013) Prognostic significance of CD151 overexpression in non-small cell lung cancer. Lung Cancer 81:109-116